Staloral Mite Allergen, maintenance course, vial 10ml, 2pcs

Composition

Active ingredient:  

Allergen extract from Dermatophagoides pteronyssinus, Dermatophagoides farinae mites in equal proportions of 10 IR/ml*,300 IR/ml

Auxiliary substances:

sodium chloride,

glycerol,

mannitol,

purified water * IR / ml-Reactivity Index-biological unit of standardization.

Pharmacological action

The exact mechanism of action of the allergen during allergen-specific immunotherapy (ASIT) is not fully understood. The following biological changes are proven: :

• the appearance of specific antibodies (IgG4), which play the role of “blocking antibodies”;
• a decrease in the level of specific IgE in plasma; 
• reduced reactivity of cells involved in an allergic reaction;
• increased activity of the interaction between Th2 and Th1, leading to a positive change in the production of cytokines (reduced IL-4 and increased -interferon) that regulate IgE production.

ASIT also inhibits the development of both the early and late phases of an immediate allergic reaction.

Indications

Allergen-specific immunotherapy (ASIT) of patients with type 1 allergic reaction (IgE-mediated), suffering from rhinitis, conjunctivitis, mild or moderate form of bronchial asthma, with increased sensitivity to house dust mites (D. pteronyssinus, D. farinae).

Contraindications

• Uncontrolled or severe bronchial asthma (forced expiratory volume < 70%);
• Autoimmune diseases, immunocomplex diseases, and immunodeficiency disorders; 
• Malignant neoplasms; Beta-blocker therapy (including topical therapy in ophthalmology);
• Hypersensitivity to one of the excipients (see the list of excipients);
• Severe inflammatory diseases of the oral mucosa, for example, erosive and ulcerative form of lichen planus, mycoses.

Side effects

Local reactions:

• oral: itching in the oral cavity, swelling, discomfort in the mouth and throat, impaired salivary glands (increased salivation or dry mouth);
• gastroenterological reactions: abdominal pain, nausea, diarrhea.

Usually, these symptoms go away quickly, and there is no need to change the dosage and treatment regimen. In case of frequent occurrence of symptoms, the possibility of continuing therapy should be reviewed.

General reactions are rare:

rhinitis, conjunctivitis, asthma, and urticaria require symptomatic treatment with H1 antagonists, beta-2 mimetics, or oral corticosteroids. The doctor should review the dosage and treatment regimen or the possibility of continuing ASIT. in extremely rare cases, generalized urticaria, angioedema, laryngeal edema, severe asthma, anaphylactic shock are possible, which requires the withdrawal of ASIT.

Rare side effects not related to Ig-E mediator reactions:

• asthenia, headache;
• exacerbation of preclinical atopic eczema;
• delayed reactions of the type of serum sickness with arthralgia, myalgia, urticaria, nausea, adenopathy, fever, which requires the withdrawal of ASIT.

All side effects should be reported to your doctor.

Interaction

Do not use at the same time as taking beta-blockers.

Concomitant use with symptomatic anti – allergic drugs (H1-antihistamines, beta-2-mimetics, corticoids, mast cell degranulation inhibitors) is possible for better tolerability of ASIT.

How to take, course of use and dosage

The effectiveness of ASIT is higher in cases where treatment is initiated in the early stages of the disease.

Dosage and treatment regimen The dosage of the drug and the scheme of its use are the same for all ages, but can be changed depending on the individual reactivity of the patient. The attending physician adjusts the dosage and treatment regimen in accordance with possible symptomatic changes in the patient and individual response to the drug. Treatment consists of two stages: initial and maintenance therapy.

1. Initial therapy begins with a daily dose of the drug at a concentration of 10 IR/ml (blue bottle cap) with a single tap on the dispenser and gradually increases the daily dosage to 10 taps. One tap on the dispenser is about 0.1 ml of the drug. Then proceed to the daily intake of the drug at a concentration of 300 IR/ml (purple bottle cap), starting with a single tap and gradually increasing the number of taps to the optimal one (well tolerated by the patient). The first stage can last 9-21 days. During this period, the maximum dosage is reached, individual for each patient (from 4 to 8 taps daily of the drug at a concentration of 300 IR/ml), after which they proceed to the second stage.

2. Maintenance therapy with a constant dose using a vial of 300 IR/ml. The optimal dose achieved at the first stage of initial therapy is continued to be taken at the second stage of maintenance therapy. Recommended dosage regimen: 4 to 8 taps on the dispenser daily or 8 taps 3 times a week. Duration of treatment Maintenance therapy is recommended for 3-5 years. If improvement does not occur after the first year of treatment, the feasibility of ASIT should be reviewed.

Break in taking the drug If you miss taking the drug for a long time, you should consult your doctor. If you missed taking the drug for less than one week, it is recommended to continue treatment without changes. If the drug is missed for more than one week at the initial stage or during maintenance therapy, it is recommended to start treatment again with a single tap on the dispenser, using the same concentration of the drug (as before the break), and then increase the number of taps, according to the scheme of the initial stage of therapy, to the optimal well-tolerated dose.

Overdose

If the prescribed dose is exceeded, the risk of side effects increases, which requires symptomatic treatment.

Special instructions

If necessary, the allergy symptoms should be stabilized with appropriate therapy before starting ASIT. Patients undergoing ASIT should always carry medications to relieve their allergy symptoms, such as corticosteroids, sympathomimetics, and antihistamines.

You should immediately consult a doctor if you experience severe itching of the palms, hands, soles of the feet, urticaria, swelling of the lips, larynx, accompanied by difficulty swallowing, breathing, voice changes. In these cases, your doctor may recommend taking epinephrine. Patients taking tricyclic antidepressants, monoamine oxidase inhibitors, increase the risk of side effects of epinephrine up to a fatal outcome. This circumstance should be taken into account when prescribing ASIT.

In case of inflammatory processes in the oral cavity (mycoses, aphthae, gum damage, tooth extraction / loss, or surgery), therapy should be interrupted until the inflammation is completely cured (at least within 7 days).

During the course of ASIT, it is possible to carry out vaccination after consultation with a doctor.

For patients, especially children, who are on a diet with reduced salt intake, it should be taken into account that the drug contains sodium chloride (one tap on the dispenser makes about 0.1 ml of the drug with a content of 5.9 mg of sodium chloride).

When traveling, make sure that the bottle is in an upright position. The bottle should be placed in a box with a protective ring on the dispenser. The bottle should be placed in the refrigerator as soon as possible.

Form of production

Sublingual drops

Active ingredient

Tick allergens

Conditions of release from pharmacies

By prescription

Dosage form

oral drops